MXPA01005169A - Promocion o inhibicion deangiogenesis y cardiovascularizacion. - Google Patents

Promocion o inhibicion deangiogenesis y cardiovascularizacion.

Info

Publication number
MXPA01005169A
MXPA01005169A MXPA01005169A MXPA01005169A MXPA01005169A MX PA01005169 A MXPA01005169 A MX PA01005169A MX PA01005169 A MXPA01005169 A MX PA01005169A MX PA01005169 A MXPA01005169 A MX PA01005169A MX PA01005169 A MXPA01005169 A MX PA01005169A
Authority
MX
Mexico
Prior art keywords
seq
polypeptide
mammal
pro1303
antibody
Prior art date
Application number
MXPA01005169A
Other languages
English (en)
Spanish (es)
Inventor
Paul J Godowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/025108 external-priority patent/WO1999028462A2/en
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/020944 external-priority patent/WO2000015792A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/en
Priority claimed from PCT/US1999/023089 external-priority patent/WO2000021996A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MXPA01005169A publication Critical patent/MXPA01005169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
MXPA01005169A 1998-12-01 1999-11-30 Promocion o inhibicion deangiogenesis y cardiovascularizacion. MXPA01005169A (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
PCT/US1998/025108 WO1999028462A2 (en) 1997-12-03 1998-12-01 Polypeptides and nucleic acids encoding the same
US11285098P 1998-12-16 1998-12-16
US11555499P 1999-01-12 1999-01-12
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
US12395799P 1999-03-12 1999-03-12
US13144599P 1999-04-28 1999-04-28
US13428799P 1999-05-14 1999-05-14
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
PCT/US1999/020944 WO2000015792A2 (en) 1998-09-14 1999-09-13 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/021547 WO2000015797A2 (en) 1998-09-17 1999-09-15 Compositions and methods for the treatment of immune related diseases
PCT/US1999/023089 WO2000021996A2 (en) 1998-10-13 1999-10-05 Methods and compositions for inhibiting neoplastic cell growth
US16250699P 1999-10-29 1999-10-29
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization

Publications (1)

Publication Number Publication Date
MXPA01005169A true MXPA01005169A (es) 2002-07-02

Family

ID=37398593

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01005169A MXPA01005169A (es) 1998-12-01 1999-11-30 Promocion o inhibicion deangiogenesis y cardiovascularizacion.

Country Status (9)

Country Link
EP (1) EP1135485B1 (https=)
JP (3) JP3695642B2 (https=)
KR (1) KR100529270B1 (https=)
AT (1) ATE458050T1 (https=)
AU (1) AU771751C (https=)
CA (1) CA2347835A1 (https=)
IL (1) IL202176A0 (https=)
MX (1) MXPA01005169A (https=)
WO (1) WO2000032221A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019991A1 (en) * 1999-09-15 2001-03-22 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2000053760A2 (en) * 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
WO2002008284A2 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
ATE405651T1 (de) 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
DE69934903T2 (de) 1998-11-10 2007-10-18 Emory University Mitogene regulatoren
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
CA2354610A1 (en) * 1998-12-09 2000-06-15 Shionogi & Co., Ltd. Human secretory phospholipase a2
EP1155117A4 (en) * 1998-12-30 2003-05-14 Millennium Pharm Inc SECRETED PROTEINS AND NUCLEIC ACIDS ENCODING THESE PROTEINS
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
CA2362885A1 (en) * 1999-03-11 2000-09-14 Mount Sinai Hospital Human kallikrein-like genes
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
EP1198568B1 (en) * 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
IL149849A0 (en) * 1999-12-09 2002-11-10 Sankyo Co A method and kit for testing an agent for treatment of hyperlipemia
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HK1051543A1 (zh) * 2000-01-12 2003-08-08 Yale University Nogo受体介导的轴突生长封锁
WO2001064856A2 (en) * 2000-02-28 2001-09-07 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
EP1283260A4 (en) 2000-04-21 2004-08-18 Takeda Chemical Industries Ltd POLYPEPTIDES OF THE INSULIN / IGF / RELAXIN FAMILY AND THEIR DNA
DE60141409D1 (de) 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
JPWO2002057448A1 (ja) * 2000-12-27 2004-05-20 第一ファインケミカル株式会社 新規ペプチド及びその活性
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003006687A2 (en) * 2001-07-10 2003-01-23 Medigene Ag Novel target genes for diseases of the heart
NZ533736A (en) * 2001-12-19 2006-09-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor and inhibiting cell growth
EP1487268A4 (en) * 2002-03-01 2005-08-24 Blood Ct Res Foundation BAX REDUCER PEPTIDES DERIVED FROM KU-70 AND THEIR USE IN THE PROTECTION OF DAMAGED CELLS
CA2480419A1 (en) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
WO2004002515A1 (ja) * 2002-06-28 2004-01-08 Takeda Chemical Industries, Ltd. 呼吸器疾患の診断・予防・治療剤
ES2346868T3 (es) 2002-08-10 2010-10-21 Yale University Antagonistas de receptor nogo.
WO2005068497A1 (en) * 2004-01-06 2005-07-28 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Iis: a novel ifn-gamma-inducible protein, member of the secretoglobin family, that modulates cellular invasion and migration
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
MX2017015260A (es) 2015-06-03 2018-02-19 Squibb Bristol Myers Co Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
CN109136275B (zh) * 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
CN114507677B (zh) * 2022-02-16 2023-09-05 中国人民解放军空军军医大学 Ndufs1基因在治疗心梗后心衰中的应用和相关产品
EP4484444A1 (en) * 2023-06-28 2025-01-01 Centre National de la Recherche Scientifique Protein and fragments thereof, and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide

Also Published As

Publication number Publication date
JP3803681B2 (ja) 2006-08-02
AU1748200A (en) 2000-06-19
AU771751C (en) 2006-04-06
JP2003524385A (ja) 2003-08-19
ATE458050T1 (de) 2010-03-15
WO2000032221A3 (en) 2000-11-23
JP4358159B2 (ja) 2009-11-04
JP2006006329A (ja) 2006-01-12
AU771751B2 (en) 2004-04-01
KR100529270B1 (ko) 2005-11-21
EP1135485B1 (en) 2010-02-17
JP3695642B2 (ja) 2005-09-14
KR20010086070A (ko) 2001-09-07
JP2005046146A (ja) 2005-02-24
IL202176A0 (en) 2010-06-16
EP1135485A2 (en) 2001-09-26
CA2347835A1 (en) 2000-06-08
WO2000032221A2 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
AU771751B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU768694B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
JP2003531811A5 (https=)
KR100543857B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제
WO2000053752A2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
US6800604B2 (en) Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
EP1212417B1 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2001040464A1 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
AU5920099A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2003259607B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
KR100678523B1 (ko) Pro840 폴리펩티드 아고니스트 또는 길항제의 확인 방법
EP1734051A2 (en) Composition and methods for the diagnosis of tumours
NZ545534A (en) Promotion or inhibition of angiogenesis and cardiovascularization
NZ540754A (en) Promotion or inhibition of angiogenesis and cardiovascularization
ZA200103707B (en) Promotion or inhibition of angiogenesis and cardio-vascularization.
WO2001019987A1 (en) Promotion or inhibition of angiogenesis and cardiovascularization
NZ532803A (en) Promotion or inhibition of angiogenesis and cardiovascularization
ZA200105990B (en) Promotion or inhibition of angiogenesis and cardiovascularization.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal